Cases & Deals

  • Home
  • Practices
  • STCube develops global patent portfolios related to Nelmastobart, an anti-BTNA1 immune checkpoint inhibitor

Share

STCube develops global patent portfolios related to Nelmastobart, an anti-BTNA1 immune checkpoint inhibitor

September 2025

Client(s) STCube Pharmaceuticals, Inc.

Jones Day is representing STCube Pharmaceuticals, Inc., a clinical-stage biotechnology company, in the development of global patent portfolios related to Nelmastobart (hSTC810), a next-generation anti-BTN1A1 immune checkpoint inhibitor designed to enhance anti-tumor immune responses. The company's technology platform integrates precision medicine and biomarker-driven strategies to enable targeted therapies for a broad range of solid tumors.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.